Navigate peer-reviewed breakthroughs by pharmacological class, genetic target, circulating biomarker, or diagnostic modality. Select any clinical entity to inspect all linked studies.
Everyday Health & Science Hubs
Indexed Entities (24)
Drug / Therapy7 Peer-Reviewed Briefings
CAR-T & Engineered Cell Therapy
Chimeric antigen receptor T-cell and adoptive cellular therapies for hematologic & autoimmune diseases.
Active Specialties:OncologyNeurologyImmunologyEndocrinology
The risk-benefit ratio observed in the DALY 2-EU study supports consideration of zamto-cel as a second-line standard treatment option for patients with relapsed or refractory large B-cell lymphoma who are ineligible for transplantation. However, there is no evidence from randomised controlled trials in patients ineligible for transplantation.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
Suppressing that response, either with preconditioning drugs or by redesigning the chimeric antigen receptor, helps make the cells and their therapeutic benefit last. Published in Cancer discovery, these peer-reviewed oncology findings provide quantitative evidence to inform clinical risk stratification, therapeutic decision-making, and follow-up trial design.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
Using a library of ready-made T-cell receptors targeting recurring mutations in TP53, clinicians have developed a personalized autologous T-cell therapy that skips the usual months of bespoke receptor hunting and has produced responses lasting 6 to 19 months in early clinical testing. Published in Cancer discovery, these peer-reviewed oncology findings provide quantitative evidence to inform clinical risk stratification, therapeutic decision-making, and follow-up trial design.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
In this nonrandomized clinical trial, a single dose of mivocabtagene autoleucel resulted in immunotherapy-free remissions with a consistent, well-tolerated safety profile, demonstrating a highly effective therapy in antibody-positive SPS with the potential for durable remissions. Long-term follow-up is ongoing.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
We propose a pragmatic revaccination approach after BCMA-targeting therapies in adult patients with autoimmune diseases, utilising minimal serologic monitoring. Future studies of these novel drugs will refine our understanding of the optimal timing and need for revaccinations in this population.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
These findings identify metabolic control of translation as a fever-sensitive checkpoint and establish arginine supplementation as a tractable strategy to enhance CAR T cell efficacy (real-world effectiveness in the trial). This effect required mTOR-dependent recruitment of the eIF4F translation-initiation complex and downstream c-MYC-driven metabolic reprogramming.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
The evidence generated by this study has the potential to advance the development of more effective cellular therapies. An inverse correlation was observed between prior lines of therapy and the proportion of naive-like T cells in both product and matched apheresis samples, suggesting a benefit of earlier intervention.
4/5 Strong Trial
Evidence Meter · 4/5
Strong Clinical Evidence
Tested directly in patients through a prospective clinical trial or large multicenter human cohort.
1 min read·Nature Medicine·
Patient & Student Companion
Everyday Lab & Drug Translator
Instant plain-English guides for common blood tests and prescriptions—what normal ranges mean, what high/low values signal, and what to ask your clinician.
Lab Marker3-Month Blood Sugar
HbA1c
Measures the percentage of red blood cell hemoglobin coated with glucose over roughly 90 days.
Normal: below 5.7% · Prediabetes: 5.7%–6.4%
6.5% or higher on two tests diagnoses diabetes; very low values can occur alongside hypoglycemia or hemolytic anemia.
Ask your doctor: “Does my HbA1c match my daily fasting/post-meal glucose trends?”
Estimated glomerular filtration rate—how many milliliters of blood your kidneys filter every minute.
Healthy adult filter rate: 90+ mL/min/1.73m²
Values persistently below 60 for 3+ months (or elevated urine albumin) mark chronic kidney disease; single dips can simply reflect dehydration or NSAID use.
Ask your doctor: “Should we pair eGFR with a urine albumin-to-creatinine test (uACR)?”